首页> Journal of medicinal chemistry> Correction to "Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design".

Correction to "Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design".

导出原文传递

翻译打印收藏纠错

第一作者： Mark,Sabat

第一单位： Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States.

作者： Mark,Sabat ^[1] ; Douglas R,Dougan ^[1] ; Jacques,Ermolieff ^[2] ; Petro,Halkowycz ^[1] ; Beverly,Knight ^[3] ; J David,Lawson ^[4] ; Nicholas,Scorah ^[1] ; Christopher R,Smith ^[4] ; Ewan R,Taylor ^[1] ; Phong,Vu ^[1] ; Corey,Wyrick ^[1] ; Haixia,Wang ^[1] ; Deepika,Balakrishna ^[1] ; Mark,Hixon ^[5] ; Loui,Madakamutil ^[6] ; Donavon,McConn ^[1]

作者单位： Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States. ^[1] Tango Therapeutics, 100 Binney Street, Suite 700, Cambridge, Massachusetts 02142, United States. ^[2] Pfizer, 10777 Science Center Drive, San Diego, California 92121, United States. ^[3] Mirati Therapeutics, Inc., 9393 Towne Centre Drive #200, San Diego, California 92121, United States. ^[4] VeriSIM Life, 1 Sansome Street Suite 3500 San Francisco, California 94104, United States. ^[5] Invivoscribe Therapeutics, Inc., 10222 Barnes Canyon Road, Building 1, San Diego, California 92121, United States. ^[6]

DOI 10.1021/acs.jmedchem.1c01685

PMID 34708652

发布时间 2021-11-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交